A single-dose live-attenuated YF17D-vectored SARS-CoV2 vaccine candidate

The explosively expanding COVID-19 pandemic urges the development of safe, efficacious and fast-acting vaccines to quench the unrestrained spread of SARS-CoV-2. Several promising vaccine platforms, developed in recent years, are leveraged for a rapid emergency response to COVID-19. We employed the l...

Full description

Saved in:
Bibliographic Details
Published in:bioRxiv 2020-07
Main Authors: Lorena Sanchez Felipe, Vercruysse, Thomas, Sharma, Sapna, Ma, Ji, Lemmens, Viktor, Dominique Van Looveren, Mahadesh Prasad Arkalagud Javarappa, Boudewijns, Robbert, Malengier-Devlies, Bert, Kaptein, Suzanne F, Liesenborghs, Laurens, De Keyzer, Carolien, Bervoets, Lindsey, Rasulova, Madina, Seldeslachts, Laura, Jansen, Sander, Michael Bright Yakass, Quaye, Osbourne, Li-Hsin, Li, Zhang, Xin, Sebastiaan Ter Horst, Mishra, Niraj, Coelmont, Lotte, Cawthorne, Christopher, Koen Van Laere, Opdenakker, Ghislain, Greetje Van De Velde, Weynand, Birgit, Teuwen, Dirk E, Matthys, Patrick, Neyts, Johan, Thibaut, Hendrik Jan, Dallmeier, Kai
Format: Article
Language:English
Subjects:
Coronaviruses
COVID-19
Immune response (cell-mediated)
Lung diseases
Lymphocytes T
Pandemics
Severe acute respiratory syndrome coronavirus 2
Vaccines
Yellow fever
Citations: Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The explosively expanding COVID-19 pandemic urges the development of safe, efficacious and fast-acting vaccines to quench the unrestrained spread of SARS-CoV-2. Several promising vaccine platforms, developed in recent years, are leveraged for a rapid emergency response to COVID-19. We employed the live-attenuated yellow fever 17D (YF17D) vaccine as a vector to express the prefusion form of the SARS-CoV-2 Spike antigen. In mice, the vaccine candidate, tentatively named YF-S0, induces high levels of SARS-CoV-2 neutralizing antibodies and a favorable Th1 cell-mediated immune response. In a stringent hamster SARS-CoV-2 challenge model, vaccine candidate YF-S0 prevents infection with SARS-CoV-2. Moreover, a single dose confers protection from lung disease in most vaccinated animals even within 10 days. These results warrant further development of YF-S0 as a potent SARS-CoV-2 vaccine candidate. Competing Interest Statement The authors have declared no competing interest.
DOI:10.1101/2020.07.08.193045